

- Ciechanover A. Intracellular protein degradation: from a vague idea thru the lysosome and the ubiquitin-proteasome system and onto human diseases and drug targeting. *Biochim Biophys Acta* 2012;1824:3–13.
- Kopp F, Hendil KB, Dahlmann B, et al. Subunit arrangement in the human 20S proteasome. *Proc Natl Acad Sci U S A* 1997;94:2939–2944.
- Wilkinson KD. Ubiquitination and deubiquitination: targeting of proteins for degradation by the proteasome. *Semin Cell Dev Biol* 2000;11:141–148.
- Braun BC, Glickman M, Kraft R, et al. The base of the proteasome regulatory particle exhibits chaperone-like activity. *Nat Cell Biol* 1999;1:221–226.
- Groll M, Ditzel L, Lowe J, et al. Structure of 20S proteasome from yeast at 2.4 Å resolution. *Nature* 1997;386:463–471.
- Borissenko L, Groll M. 20S proteasome and its inhibitors: crystallographic knowledge for drug development. *Chem Rev* 2007;107:687–717.
- Kloetzel PM, Ossendorp F. Proteasome and peptidase function in MHC-class-I-mediated antigen presentation. *Curr Opin Immunol* 2004;16:76–81.
- Griffin TA, Nandi D, Cruz M, et al. Immunoproteasome assembly: cooperative incorporation of interferon gamma (IFN-gamma)-inducible subunits. *J Exp Med* 1998;187:97–104.
- Tanahashi N, Murakami Y, Minami Y, et al. Hybrid proteasomes. Induction by interferon-gamma and contribution to ATP-dependent proteolysis. *J Biol Chem* 2000;275:14336–14345.
- Adams J. The proteasome: a suitable antineoplastic target. *Nat Rev Cancer* 2004;4:349–360.
- Vinitzky A, Michaud C, Powers JC, et al. Inhibition of the chymotrypsin-like activity of the pituitary multicatalytic proteinase complex. *Biochemistry* 1992;31:9421–9428.
- Orlowski RZ, Eswara JR, Lafond-Walker A, et al. Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor. *Cancer Res* 1998;58:4342–4348.
- Imajoh-Ohmi S, Kawaguchi T, Sugiyama S, et al. Lactacystin, a specific inhibitor of the proteasome, induces apoptosis in human monoblast U937 cells. *Biochem Biophys Res Commun* 1995;217:1070–1077.
- Shinohara K, Tomioka M, Nakano H, et al. Apoptosis induction resulting from proteasome inhibition. *Biochem J* 1996;317:385–388.
- Delic J, Masdehors P, Omura S, et al. The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF-alpha-initiated apoptosis. *Br J Cancer* 1998;77:1103–1107.
- Meng L, Mohan R, Kwok BH, et al. Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. *Proc Natl Acad Sci U S A* 1999;96:10403–10408.
- Meng L, Kwok BH, Sin N, et al. Eponemycin exerts its antitumor effect through the inhibition of proteasome function. *Cancer Res* 1999;59:2798–2801.
- Dick LR, Fleming PE. Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy. *Drug Discov Today* 2010;15:243–249.
- Kirk CJ. Discovery and development of second-generation proteasome inhibitors. *Semin Hematol* 2012;49:207–214.
- Bross PF, Kane R, Farrell AT, et al. Approval summary for bortezomib for injection in the treatment of multiple myeloma. *Clin Cancer Res* 2004;10:3954–3964.
- Hemdon TM, Deisseroth A, Kaminskas E, et al. U.S. Food and Drug Administration approval: carfilzomib for the treatment of multiple myeloma. *Clin Cancer Res* 2013;19:4559–4563.
- Bennett MK, Kirk CJ. Development of proteasome inhibitors in oncology and autoimmune diseases. *Curr Opin Drug Discov Devel* 2008;11:616–625.
- Adams J, Behnke M, Chen S, et al. Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. *Bioorg Med Chem Lett* 1998;8:333–338.
- Groll M, Berkers CR, Ploegh HL, et al. Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome. *Structure* 2006;14:451–456.
- Groll M, Huber R, Potts BC. Crystal structures of Salinosporamide A (NPI-0052) and B (NPI-0047) in complex with the 20S proteasome reveal important consequences of beta-lactone ring opening and a mechanism for irreversible binding. *J Am Chem Soc* 2006;128:5136–5141.
- Groll M, Kim KB, Kairies N, et al. Crystal structure of epoxomicin: 20S proteasome reveals a molecular basis for selectivity of a' b'-epoxyketone proteasome inhibitors. *J Am Chem Soc* 2000;122:1237–1238.
- Kisselev AF, van der Linden WA, Overkleeft HS. Proteasome inhibitors: an expanding army attacking a unique target. *Chem Biol* 2012;19:99–115.
- Arastu-Kapur S, Anderl JL, Kraus M, et al. Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events. *Clin Cancer Res* 2011;17:2734–2743.
- Kisselev AF, Callard A, Goldberg AL. Importance of the different proteolytic sites of the proteasome and the efficacy of inhibitors varies with the protein substrate. *J Biol Chem* 2006;281:8582–8590.
- Parlati F, Lee SJ, Aujay M, et al. Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome. *Blood* 2009;114:3439–3447.
- Britton M, Lucas MM, Downey SL, et al. Selective inhibitor of proteasome's caspase-like sites sensitizes cells to specific inhibition of chymotrypsin-like sites. *Chem Biol* 2009;16:1278–1289.
- Mirabella AC, Pletnev AA, Downey SL, et al. Specific cell-permeable inhibitor of proteasome trypsin-like sites selectively sensitizes myeloma cells to bortezomib and carfilzomib. *Chem Biol* 2011;18:608–618.
- Demo SD, Kirk CJ, Aujay MA, et al. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. *Cancer Res* 2007;67:6383–6391.
- Kupperman E, Lee EC, Cao Y, et al. Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. *Cancer Res* 2010;70:1970–1980.
- Piva R, Ruggeri B, Williams M, et al. CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib. *Blood* 2008;111:2765–2775.
- Chauhan D, Singh AV, Aujay M, et al. A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma. *Blood* 2010;116:4906–4915.
- Zhou HJ, Aujay MA, Bennett MK, et al. Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047). *J Med Chem* 2009;52:3028–3038.
- Chauhan D, Catley L, Li C, et al. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. *Cancer Cell* 2005;8:407–419.
- Chauhan D, Singh A, Brahmandam M, et al. Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma. *Blood* 2008;111:1654–1664.
- Chauhan D, Tian Z, Zhou B, et al. In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells. *Clin Cancer Res* 2011;17:5311–5321.
- Kuhn DJ, Chen Q, Voorhees PM, et al. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. *Blood* 2007;110:3281–3290.
- Suzuki E, Demo S, Deu E, et al. Molecular mechanisms of bortezomib resistant adenocarcinoma cells. *PLoS One* 2011;6:e27996.
- Zhang HG, Wang J, Yang X, et al. Regulation of apoptosis proteins in cancer cells by ubiquitin. *Oncogene* 2004;23:2009–2015.
- Fernandez Y, Verhaegen M, Miller TP, et al. Differential regulation of noxa in normal melanocytes and melanoma cells by proteasome inhibition: therapeutic implications. *Cancer Res* 2005;65:6294–6304.
- Nikiforov MA, Riblett M, Tang WH, et al. Tumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition. *Proc Natl Acad Sci U S A* 2007;104:19488–19493.
- Qin JZ, Ziffra J, Stennett L, et al. Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells. *Cancer Res* 2005;65:6282–6293.
- Wang Q, Mora-Jensen H, Weniger MA, et al. ERAD inhibitors integrate ER stress with an epigenetic mechanism to activate BH3-only protein NOXA in cancer cells. *Proc Natl Acad Sci U S A* 2009;106:2200–2205.
- Mannava S, Zhuang D, Nair JR, et al. KLF9 is a novel transcriptional regulator of bortezomib- and LBH589-induced apoptosis in multiple myeloma cells. *Blood* 2012;119:1450–1458.
- Koepp DM, Harper JW, Elledge SJ. How the cyclin became a cyclin: regulated proteolysis in the cell cycle. *Cell* 1999;97:431–434.
- Pagano M, Tam SW, Theodoras AM, et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. *Science* 1995;269:682–685.
- Wan F, Lenardo MJ. The nuclear signaling of NF-kappaB: current knowledge, new insights, and future perspectives. *Cell Res* 2010;20:24–33.
- Annunziata CM, Davis RE, Demchenko Y, et al. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. *Cancer Cell* 2007;12:115–130.
- Chapman MA, Lawrence MS, Keats JJ, et al. Initial genome sequencing and analysis of multiple myeloma. *Nature* 2011;471:467–472.
- Keats JJ, Fonseca R, Chesi M, et al. Promiscuous mutations activate the non-canonical NF-kappaB pathway in multiple myeloma. *Cancer Cell* 2007;12:131–144.
- Meister S, Schubert U, Neubert K, et al. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. *Cancer Res* 2007;67:1783–1792.
- Obeng EA, Carlson LM, Gutman DM, et al. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. *Blood* 2006;107:4907–4916.
- Shabaneh TB, Downey SL, Goddard AL, et al. Molecular basis of differential sensitivity of myeloma cells to clinically relevant bolus treatment with bortezomib. *PLoS One* 2013;8:e56132.
- Papadopoulos KP, Burris HA III, Gordon M, et al. A phase I/II study of carfilzomib 2-10-min infusion in patients with advanced solid tumors. *Cancer Chemother Pharmacol* 2013;72:861–868.
- Papandreou CN, Daliani DD, Nix D, et al. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. *J Clin Oncol* 2004;22:2108–2121.
- Wang Z, Yang J, Kirk C, et al. Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib. *Drug Metab Dispos* 2013;41:230–237.
- Yang J, Wang Z, Fang Y, et al. Pharmacokinetics, pharmacodynamics, metabolism, distribution, and excretion of carfilzomib in rats. *Drug Metab Dispos* 2011;39:1873–1882.

62. Meiners S, Heyken D, Weller A, et al. Inhibition of proteasome activity induces concerted expression of proteasome genes and de novo formation of mammalian proteasomes. *J Biol Chem* 2003;278:21517–21525.
63. Lonial S, Waller EK, Richardson PG, et al. Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. *Blood* 2005;106:3777–3784.
64. Richardson PG, Briemberg H, Jagannath S, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. *J Clin Oncol* 2006;24:3113–3120.
65. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. *N Engl J Med* 2003;348:2609–2617.
66. Jagannath S, Barlogie B, Berenson J, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. *Br J Haematol* 2004;127:165–172.
67. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib plus melphalan and prednisone for relapsed multiple myeloma. *N Engl J Med* 2005;352:2487–2498.
68. Jagannath S, Brian D, Wolf JL, et al. A phase 2 study of bortezomib as first-line therapy in patients with multiple myeloma. *Blood* 2004;104:333.
69. San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. *N Engl J Med* 2008;359:906–917.
70. San Miguel JF, Schlag R, Khuageva NK, et al. Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma. *J Clin Oncol* 2013;31:448–455.
71. Orlowski RZ, Voorhees PM, Garcia RA, et al. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. *Blood* 2005;105:3058–3065.
72. Orlowski RZ, Nagler A, Sonneveld P, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. *J Clin Oncol* 2007;25:3892–3901.
73. Sonneveld P, Hajek R, Nagler A, et al. Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy. *Cancer* 2008;112:1529–1537.
74. Richardson PG, Xie W, Jagannath S, et al. A phase II trial of lenalidomide, bortezomib and dexamethasone in patients with relapsed and relapsed/refractory myeloma. *Blood* 2014;123:1461–1469.
75. Kapoor P, Ramakrishnan V, Rajkumar SV. Bortezomib combination therapy in multiple myeloma. *Semin Hematol* 2012;49:228–242.
76. Richardson PG, Weller E, Lonial S, et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. *Blood* 2010;116:679–686.
77. Belch A, Kourouktsis CT, Crump M, et al. A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150. *Ann Oncol* 2007;18:116–121.
78. Fisher RI, Bernstein SH, Kahl BS, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. *J Clin Oncol* 2006;24:4867–4874.
79. Milano A, Laffaioli RV, Caponigro F. The proteasome: a worthwhile target for the treatment of solid tumours? *Eur J Cancer* 2007;43:1125–1133.
80. Fanucchi MP, Fossella FV, Belt R, et al. Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer. *J Clin Oncol* 2006;24:5025–5033.
81. Ramaswamy B, Phelps MA, Baiocchi R, et al. A dose-finding, pharmacokinetic and pharmacodynamic study of a novel schedule of flavopiridol in patients with advanced solid tumors. *Invest New Drugs* 2012;30:629–638.
82. Luu T, Chow W, Lim D, et al. Phase I trial of fixed-dose rate gemcitabine in combination with bortezomib in advanced solid tumors. *Anticancer Res* 2010;30:167–174.
83. Everly MJ, Everly JJ, Susskind B, et al. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. *Transplantation* 2008;86:1754–1761.
84. Neubert K, Meister S, Moser K, et al. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. *Nat Med* 2008;14:748–755.
85. O'Connor OA, Stewart AK, Vallone M, et al. A phase I dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies. *Clin Cancer Res* 2009;15:7085–7091.
86. Alsina M, Trudel S, Furman RR, et al. A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma. *Clin Cancer Res* 2012;18:4830–4840.
87. Jagannath S, Vij R, Stewart AK, et al. An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma. *Clin Lymphoma Myeloma Leuk* 2012;12:310–318.
88. Siegel DS, Martin T, Wang M, et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. *Blood* 2012;120:2817–2825.
89. Siegel DS, Martin T, Wang M, et al. Results of PX-171-003-A1, an open-label, single-arm, phase 2 (Ph 2) study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (MM). *Blood* 2012;120:2817–2825.
90. Vij R, Siegel DS, Jagannath S, et al. An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib. *Br J Haematol* 2012;158:739–748.
91. Vij R, Wang M, Kaufman JL, et al. An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naïve patients with relapsed and/or refractory multiple myeloma. *Blood* 2012;119:5661–5670.
92. Papadopoulos K, Capua Siegel DS, Singhal SB, et al. Phase 1b evaluation of the safety and efficacy of a 30-minute IV infusion of carfilzomib in patients with relapsed and/or refractory multiple myeloma. *Blood* 2010;116:3024.
93. Lee SJ, Levitsky K, Parlati F, et al. Clinical activity of carfilzomib correlates with inhibition of multiple proteasome subunits: application of a novel pharmacodynamics assay. (In press).
94. Wang M, Martin T, Bensinger W, et al. Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. *Blood* 2013;122:3122–3128.
95. Jakubowiak AJ, Dytfield D, Griffith KA, et al. A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a front-line treatment for multiple myeloma. *Blood* 2012;120:1801–1809.
96. Richardson PG, Baz R, Wang L, et al. Investigational agent MLN9708, an oral proteasome inhibitor, in patients (Pts) with relapsed and/or refractory multiple myeloma (MM): results from the expansion cohorts of a phase 1 dose-escalation study. *Blood* 2011;118:301.
97. Richardson PG, Spencer A, Cannell P, et al. Phase 1 clinical evaluation of twice-weekly marizomib (NPI-0052), a novel proteasome inhibitor, in patients with relapsed/refractory multiple myeloma (MM). *Blood* 2011;118:302.
98. Roy V, Reeder C, LaPlant BR, et al. Phase 2 trial Of single agent MLN9708 in patients with relapsed multiple myeloma not refractory to bortezomib. *Blood* 2013;122:1944.
99. Hofmeister CC, Rosenbaum CA, Httut M, et al. Twice-weekly oral MLN9708 (ixazomib citrate), an investigational proteasome inhibitor, in combination with lenalidomide (len) and dexamethasone (dex) in patients (pts) with newly diagnosed multiple myeloma (MM): final phase 1 results and phase 2 data. *Blood* 2013;122:555.
100. Papadopoulos KP, Mendelson DS, Tolcher AW, et al. A phase I, open-label, dose-escalation study of the novel oral proteasome inhibitor (PI) ONX 0912 in patients with advanced refractory or recurrent solid tumors. *Blood* 2011;29:3075.
101. Kaufman JL, Siegel DS, Vij R, et al. Clinical profile of single-agent modified-release oprozomib tablets in patients (pts) with hematologic malignancies: updated results from a multicenter, open-label, dose escalation phase 1b/2 study. *Blood* 2013;122:3184.
102. Mulligan G, Mitsiades C, Bryant B, et al. Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. *Blood* 2007;109:3177–3188.
103. Loehr A, Degenhardt JD, Kwei KA, et al. Immunoglobulin expression is a major determinant of patient sensitivity to proteasome inhibitors. *Blood* 2013;122:1903.
104. Leung-Hagesteijn C, Erdmann N, Cheung G, et al. Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma. *Cancer Cell* 2013;24:289–304.